148 related articles for article (PubMed ID: 19062156)
1. Editorial comment on: External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Giannarini G; Autorino R
Eur Urol; 2010 Jan; 57(1):109-10. PubMed ID: 19062156
[No Abstract] [Full Text] [Related]
2. Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Blute ML
Eur Urol; 2010 Jan; 57(1):110-1. PubMed ID: 19062158
[No Abstract] [Full Text] [Related]
3. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
[TBL] [Abstract][Full Text] [Related]
4. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
[TBL] [Abstract][Full Text] [Related]
5. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.
Ficarra V; Martignoni G; Lohse C; Novara G; Pea M; Cavalleri S; Artibani W
J Urol; 2006 Apr; 175(4):1235-9. PubMed ID: 16515968
[TBL] [Abstract][Full Text] [Related]
6. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
Parker AS; Kosari F; Lohse CM; Houston Thompson R; Kwon ED; Murphy L; Riehle DL; Blute ML; Leibovich BC; Vasmatzis G; Cheville JC
Cancer; 2006 Jul; 107(1):37-45. PubMed ID: 16736510
[TBL] [Abstract][Full Text] [Related]
7. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
[TBL] [Abstract][Full Text] [Related]
8. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.
Ficarra V; Novara G; Galfano A; Brunelli M; Cavalleri S; Martignoni G; Artibani W
BJU Int; 2009 Jan; 103(2):165-70. PubMed ID: 18782313
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
Yoo C; Song C; Hong JH; Kim CS; Ahn H
J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
[TBL] [Abstract][Full Text] [Related]
10. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma.
Blute ML; Itano NB; Cheville JC; Weaver AL; Lohse CM; Zincke H
J Urol; 2003 Apr; 169(4):1276-81. PubMed ID: 12629342
[TBL] [Abstract][Full Text] [Related]
11. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
12. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma.
Blute ML; Leibovich BC; Cheville JC; Lohse CM; Zincke H
J Urol; 2004 Aug; 172(2):465-9. PubMed ID: 15247704
[TBL] [Abstract][Full Text] [Related]
13. Outcomes following partial nephrectomy by tumor size.
Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
[TBL] [Abstract][Full Text] [Related]
14. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
[TBL] [Abstract][Full Text] [Related]
15. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates.
Crispen PL; Breau RH; Allmer C; Lohse CM; Cheville JC; Leibovich BC; Blute ML
Eur Urol; 2011 Jan; 59(1):18-23. PubMed ID: 20933322
[TBL] [Abstract][Full Text] [Related]
16. Editorial comment.
Campbell SC; Lane BR
J Urol; 2010 Feb; 183(2):485; discussion 485. PubMed ID: 20006871
[No Abstract] [Full Text] [Related]
17. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology.
Pichler M; Hutterer GC; Chromecki TF; Jesche J; Kampel-Kettner K; Rehak P; Pummer K; Zigeuner R
J Urol; 2011 Nov; 186(5):1773-7. PubMed ID: 21944989
[TBL] [Abstract][Full Text] [Related]
18. Lymph node dissection is not obsolete in clinically node-negative renal cell carcinoma patients.
Van Poppel H
Eur Urol; 2011 Jan; 59(1):24-5. PubMed ID: 20943309
[No Abstract] [Full Text] [Related]
19. Editorial comment.
Russo P
Urology; 2010 Feb; 75(2):275-6; author reply 276. PubMed ID: 20152477
[No Abstract] [Full Text] [Related]
20. The use of simplified versions of the Fuhrman nuclear grading system in clinical practice requires the agreement of a multidisciplinary panel of experts.
Ficarra V; Novara G; Martignoni G
Eur Urol; 2009 Nov; 56(5):782-4; discussion 784-5. PubMed ID: 19660853
[No Abstract] [Full Text] [Related]
[Next] [New Search]
